Houston-based biotechnology company Coya Therapeutics recently reported additional biomarker and brain imaging results from an open-label proof-of-concept clinical study in patients with mild to moderate Alzheimer's Disease (AD), in which low-dose interleukin 2 administration significantly improved AD patients’ conditions.

Presenting the results of the study at the LD Micro Conference in Los Angeles on June 7, 2023, the company reported that the trial in eight mild to moderate AD patients showed a statistically significant reduction in the expression of three well-known proinflammatory cytokines and showed a lack of cognitive decline of the patients throughout the study.

Furthermore, researchers reported a case study in which pre-treatment and post-treatment Positron Emission Tomography (PET) brain scans in a patient showed a reduction in nerve inflammations in the cerebral cortex, including hippocampal regions of the brain after being treated with low-dose Interleukin-2.

According to the researchers, the patient's improvement in cognitive function was related to the reduction in inflammation.

Read More:

The trial's researchers previously revealed that COYA 301 therapy restored peripheral Treg function and numbers, drastically reduced levels of systemic chemokines CCL11, CCL2, and cytokine IL-15, and was well tolerated.

The company further informed that an academic phase 2 double-blind randomised trial is underway at Houston Methodist for using low-dose IL-2 in up to 46 mild to moderate AD patients, supported by the Gates Foundation and Alzheimer's Association.

Commenting on the trial findings, founder and Chief Executive Officer of Coya, Dr Howard H Berman, said, “We believe these additional data further support our Treg-focused approach to develop safe and effective treatments for neurodegenerative diseases of high unmet need.”

“We remain excited about the outcome of our studies with COYA 301 in AD and COYA 302 in ALS and look forward to the next steps in progressing these programs,” he added.